Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://www.rdinvesting.com/ and get exclusive access to our numerous stock reports and market updates.
Colgate-Palmolive Company (NYSE: CL) shares declined 1.05 percent to close at $59.30 a share Monday. The stock traded between $59.10 and $60.54 on volume of 5.17 million shares traded. Analysts at Morgan Stanley have recently upgraded the company’s rating to "overweight" from "equal weight". Shares of Colgate-Palmolive have gained approximately 13.0 percent year-to-date.
Find out more about Colgate-Palmolive including full access to the free equity report at:
www.RDInvesting.com/CL
Marketo Inc. (NASDAQ: MKTO) shares gained 1.24 percent to close at $31.88 a share Monday. The stock traded between $29.17 and $31.98 on volume of 512,787 shares traded. Analysts at Wells Fargo have recently initiated coverage on the company with an "outperform" rating. Shares of Marketo have gained approximately 38.0 percent year-to-date.
Find out more about Marketo including full access to the free equity report at:
www.RDInvesting.com/MKTO
ORBCOMM Inc. (NASDAQ: ORBC) shares increased 1.95 percent to close at $5.24 a share Monday. The stock traded between $5.02 and $5.51 on volume of 265,105 shares traded. Analysts at Craig-Hallum have recently upgraded the company’s rating to "buy" from "hold". Shares of ORBCOMM have gained approximately 33.0 percent year-to-date.
Find out more about ORBCOMM including full access to the free equity report at:
www.RDInvesting.com/ORBC
Synthetic Biologics Inc. (NYSEMKT: SYN) shares declined 1.75 percent to close at $1.68 a share Monday. The stock traded between $1.65 and $1.97 on volume of 235,967 shares traded. Analysts at Maxim Group have recently initiated coverage on the company with a "buy" rating. Shares of Synthetic Biologics have fallen approximately 4.5 percent year-to-date.
Find out more about Synthetic Biologics including full access to the free equity report at:
www.RDInvesting.com/SYN
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
info@rdinvesting.com